CD86 and Hodgkins lymphoma: Lymphoma cells express CD70, CD80, CD86, and PD-L1 immune checkpoints that downregulate effector T-cells including Th17 [80], and that allowed clinical approval of CIs for Hodgkin’s lymphoma (HL) and primary mediastinal B-cell lymphoma [81,82].